Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 48 recommendations for 17 medicines and 4 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
8.2.3. Immunomodulators
  1. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    • Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver
  2. Bevacizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
    Indications
    Hepatocellular carcinoma of liver
  3. Blinatumomab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
    Indications
    B lymphoblastic leukaemia or lymphoma, not elsewhere classified
  4. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung
  5. Daratumumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  6. Dostarlimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of corpus uteri
  8. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  9. Ipilimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin
  10. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  11. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Melanoma of skin Other specified malignant neoplasms of bronchus or lung Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach
  12. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  13. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
    Indications
    Melanoma of skin Malignant neoplasms of cervix uteri Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Adenocarcinoma of stomach Squamous cell carcinoma of hypopharynx and variants Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Carcinoma of breast, specialised type Squamous cell carcinoma of nasopharynx Squamous cell carcinoma of oesophagus Malignant neoplasms of oesophagogastric junction Therapeutic equivalent to nivolumab for Melanoma of skin
  14. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  15. Tislelizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    • Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
    • Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
    Indications
    Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oesophagus
  16. Toripalimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Malignant neoplasms of nasopharynx Squamous cell carcinoma of oesophagus
  17. Tremelimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung